ATP-ase as a potential drug target for cancer, tumor growth and cellular functions

International Journal of Human Genetics

Volumn 12, Issue 3, 2012, Pages 151-156

  Sakthivel, Srinivasan ^a,b  

^a BHARATHIDASAN UNIVERSITY   (India)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

ATP ase; Cell functions; Heat shock protein; Hsp 70 and Hsp 90 cell proliferation; Nucleotide binding domains

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; CHAPERONE; CHAPERONIN 60; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CELL FUNCTION; CELL PROLIFERATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME SUBSTRATE COMPLEX; HUMAN; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN UNFOLDING; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

EID: 84866948261     PISSN: 09723757     EISSN: None     Source Type: Journal    
DOI: 10.1080/09723757.2012.11886177     Document Type: Article

References (50)

1. Benson JD, Chen YN, Cornell-Kenon SA 2006. Validating cancer drug targets. Nature, 441: 451-456.
2. Biamonte MA, Van de WR, Arndt JW, Scannevin RH, Perret D et al. 2010. Heat shock protein 90: inhibitors in clinical trials. J Med Chem, 53(1): 3-17.
3. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR 2006. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci, 31: 164-172.
4. Chene P 2002. ATPases as drug targets: learning from their structure. Nat Rev Drug Discov, 1(9): 665-673.
5. Chiosis G, Vilenchik M, Kim J, Solit D 2004. Hsp90: the vulnerable chaperone. Drug Discov, 9: 881-888.
6. Collins I, Workman P 2006. New approaches to molecular cancer therapeutics. Nat Chem Biol, 2: 689-700.
7. Da Rocha Dias S, Friedlos F, Light Y 2005. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-emethoxygelda-namycin. Cancer Res, 65: 10686-10691.
8. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J 2006. Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discovery Dev, 9(4): 483-495
9. Gaspar N, Sharp SY, Pacey S, Jones D, Walton M, et al, 2009. Acquired resistance to 17-allylamino-17-demethoxy- eldanamycin (tanespimycin) in glioblastoma cells. Cancer Res, 69(5): 1966-1975.
10. Grbovic OM, Basso AD, Sawai A 2006. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci, 103: 57-62.
11. Greenman C, Stephans P, Smith R 2007. Patterns of somatic mutation in human cancer genomes. Nature, 446: 153-158.
12. Kamal AL, Thao J, 2003. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature, 425: 407-410.
13. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, et al.2009. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem, 9(15): 1479-1492.
14. Li Y, Yang J, Li S et al, 2011. N-myc downstream-regulated gene 2, a novel estrogen-targeted gene, is involved in the regulation of Na+/K+-ATPase. J Biol Chem, 286(37): 32289-32299.
15. Mayer MP, Bukau B 2005. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci, 62(6): 670-684.
16. McDonald EP, Workman A, Jones K 2007. Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer. Curr Top Med Chem, 6: 1091-1107.
17. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, et al.2004. Simultaneous Inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther, 3(5): 551-566.
18. Neckers L. 2006. Using natural product inhibitors to validate HSP90 as a molecular target in cancer. Curr Med Chem, 6: 1163-1171.
19. Nylandsted J, Brand K., Jaattela M2000. Heat shock protein 70 is Required for the survival of cancer cells. Ann NY Acad Sci, 926: 122-125.
20. Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, et al, 2002. Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res, 62(24): 7139-7142.
21. O'Reilly KE, Rojo F, She QB 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res, 66: 1500-1508.
22. Pearl LH, Prodromou C 2006. Structure and mechanism of Hsp90 molecular chaperone machinery. Ann Rev Biochem, 75: 271-294.
23. Pick E, Kluger Y, Giltnane JM 2007. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res, 67: 2932-2937.
24. Ritossa F 1962. A new puffing pattern induced by temperature shock and DNP in Drosophila. Experentia, 19: 571-573.
25. Ritossa F 1996. Discovery of the heat shock response. Cell Stress Chaperones, 1: 97-98.
26. Roccaro AM, Hideshima T, Richardson PG 2006.Bortezomib as an antitumor agent. Curr Pharm Biotechnol, 7: 441-448.
27. Rosen N, She QB 2006. AKT and cancer-is it all mTOR. Cancer Cell, 10: 254-256.
28. Rutherford SL, Lindquist S 1998. Hsp90 as a capacitor for morphological evolution. Nature, 396: 336-342.
29. Sharma SV, Agatsuma T, Nakano H 1998. Targeting of the protein chaperone HSP90, by the transformation suppressing agent. Oncogene, 16: 2639-2645.
30. Sharp S, Workman P 2006. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res, 95: 323-348.
31. She QB, Solit DB, Ye Q 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell, 8: 287-297.
32. Shimamura T, Lowell AM, Engelman JA, Shapiro GI 2005. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res, 65: 6401-6408.
33. Sjoblom TS, Jones LD, et al. 2006. Drugging the cancer chaperone HSP90 11 sequences of human breast and colorectal cancers. Science, 314: 268-274.
34. Solit DB, Rosen N 2006. Hsp90: a novel target for cancer therapy. Curr Top Med Chem, 6: 1205-1214.
35. Taldone T, Gozman A, Maharaj R, Chiosis, G 2008. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol, 8(4): 370-374.
36. Taldone T, Sun W, Chiosis G 2009. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem, 17(6): 2225-2235.
37. Weinstein I.B 2002. Cancer. Addiction to oncogenes, the Achilles heal of cancer. Science, 297: 63-64.
38. Whitesell, L, Lindquist S 2005. HSP90 and the chaperoning of cancer. Nat Rev Cancer, 5: 761-772.
39. Whitesell, L, Lindquist SL 2005. HSP90 and the chaperoning of cancer. Nat Rev Cancer, 5(10): 761-772.
40. Whitesell LR, Bagatell, Falsey R 2003. The stress response: Implications for the development of Hp90 inhibitors. Curr Cancer Drug Target, 3: 349-358.
41. Workman P, Burrows F, Neckers L, Rosen N 2007. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation on oncogene addiction and tumor stress. Ann NY Acad Sci, 1113 (Stress Responses in Biology and Medicine), 202-216.
42. Workman P 2004. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperones. Cancer Lett, 206: 149-157.
43. Workman P 2005. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Symp Quant Biol, 70: 499-515.
44. Workman P 2003. Overview: Translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets, 3: 297-300.
45. Xu W,Neckers L 2007. Targeting the molecular chaperone heat shock protein 90 provides a multi-faceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res, 13: 1625-1629.
46. Xu W, Yuan W, Xiang Z et al. 2005. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol, 12: 120-126.
47. Yeyati PL, Bancewicz RM, Maule JM, Van heyningen V 2007. Hsp90 selectively modulates phenotype in vertebrate development. PLoS Genetics, 3e 43: 431-447.
48. Young, JC, Agashe VR, Siegers K, Hartl FU 2004. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol, 5(10): 781-791.
49. Young JC, Barral JM, Ulrich HF 2003. More than folding:localized functions of cytosolic chaperones. Trends Biochem Sci, 28(10): 541-547.
50. Zhang H, Burrows F 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med, 82: 488-499.